Phosphoric Acid Dipotassium

• 分子结构分类: 无机化合物 - 混合金属/非金属化合物 - 碱金属含氧阴离子化合物
• 英文名称: Phosphoric Acid Dipotassium
• 英文别名: dipotassium;hydron;phosphate
• 化学式: HK2O4P
• 分子量: 174.176
• InChiKey: ZPWVASYFFYYZEW-UHFFFAOYSA-L

计算性质

• 辛醇/水分配系数(LogP)：
  -8.18
• 重原子数：
  7
• 可旋转键数：
  0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  83.4
• 氢给体数：
  1
• 氢受体数：
  4

ADMET

代谢

磷酸盐是细胞内主要的阴离子，它参与提供物质代谢所需的能量，并对几乎所有器官和组织中的重要代谢和酶促反应作出贡献。

Phosphate is a major intracellular anion which participates in providing energy for metabolism of substances and contributes to important metabolic and enzymatic reactions in almost all organs and tissues.

来源:DrugBank

毒理性

• 解毒与急救

基本治疗：建立专利气道。如有必要，进行吸痰。观察呼吸不足的迹象，如有必要，协助通气。通过非循环呼吸面罩以6至12升/分钟的速度给予氧气。监测肺水肿，并在必要时进行治疗……。监测休克，并在必要时进行治疗……。对于眼睛污染，立即用水冲洗眼睛。在运输过程中，用生理盐水连续冲洗每只眼睛……。不要使用催吐剂。对于摄入，如果患者能吞咽，有强烈的干呕反射，且不流口水，则用水冲洗口腔，并给予5毫升/千克，最多200毫升的水进行稀释……。不要尝试中和。在去污染后，用干燥的无菌敷料覆盖皮肤烧伤……。/无机碱/碱性腐蚀剂及相关化合物/

Basic treatment: Establish a patent airway. Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if necessary. Administer oxygen by nonrebreather mask at 6 to 12 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with normal saline during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 mL/kg up to 200 mL of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool ... . Do not attempt to neutralize. Cover the skin burns with dry sterile dressings after decontamination ... . /Inorganic Bases/Alkaline Corrosives and Related Compounds/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 解毒与急救

高级治疗：对于失去意识或呼吸停止的患者，考虑进行口咽或鼻咽气管插管以控制气道。在出现上呼吸道阻塞的最初迹象时，可能需要尽早进行插管。使用带有气囊阀面罩的装置进行正压通气技术可能有益。监测心率和必要时治疗心律失常。开始静脉输液D5W TKO/SRP：“保持开放”，最低流量/。如果出现低血容量的迹象，使用乳酸钠林格液。注意肺水肿的迹象。对于伴有低血容量迹象的低血压，谨慎输液。注意液体过载的迹象。考虑使用药物治疗肺水肿。使用丙美卡因氢氯化物协助眼部冲洗。/无机碱/碱性腐蚀剂及相关化合物/

Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious or in respiratory arrest. Early intubation, at the first signs of upper airway obstruction, may be necessary. Positive-pressure ventilation techniques with a bag-valve-mask device may be beneficial. Monitor cardiac rhythm and treat arrhythmias as necessary ... . Start an IV of D5W TKO /SRP: "To keep open", minimal flow rate/. Use lactated Ringer's if signs of hypovolemia are present. Watch for signs of pulmonary edema. For hypotension with signs of hypovolemia, administer fluid cautiously. Watch for signs of fluid overload ... . Consider drug therapy for pulmonary edema ... . Use proparacaine hydrochloride to assist eye irrigation ... . /Inorganic Bases/Alkaline Corrosives and Related compounds/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 人类毒性摘录

通过口腔引起的急性钾中毒是罕见的，因为大剂量的单次服用通常会引起呕吐，并且在没有预先存在的肾脏损伤的情况下，钾会迅速被排出体外。/钾盐/

ACUTE POTASSIUM INTOXICATION BY MOUTH IS RARE BECAUSE LARGE SINGLE DOSES USUALLY INDUCE VOMITING & BECAUSE IN ABSENCE OF PREEXISTING KIDNEY DAMAGE, POTASSIUM IS RAPIDLY EXCRETED. /POTASSIUM SALTS/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 人类毒性摘录

口服钾盐的副作用可能包括恶心、呕吐、腹泻和腹部不适。

SIDE EFFECTS OF /ORAL/ POTASSIUM SALTS MAY INCLUDE NAUSEA, VOMITING, DIARRHEA, AND ABDOMINAL DISCOMFORT. /POTASSIUM SALTS/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 人类毒性摘录

口腔钾过量的临床迹象和症状包括四肢感觉异常、乏力、精神混乱、腿部无力或沉重、弛缓性瘫痪、皮肤发冷、灰色苍白、外周血管衰竭导致血压下降、心脏心律不齐和心脏传导阻滞。/钾盐/

CLINICAL SIGNS AND SYMPTOMS OF /ORAL/ POTASSIUM OVERDOSAGE INCLUDE PARESTHESIAS OF THE EXTREMITIES, LISTLESSNESS, MENTAL CONFUSIONS, WEAKNESS OR HEAVINESS OF THE LEGS, FLACCID PARALYSIS, COLD SKIN, GRAY PALLOR, PERIPHERAL VASCULAR COLLAPSE WITH FALL IN BLOOD PRESSURE, CARDIAC ARRHYTHMIAS, AND HEART BLOCK. /POTASSIUM SALTS/

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

• 吸收

钾盐能很好地从胃肠消化道被吸收。在某些物种的小肠中可能会发生净磷吸收，但在马中，这主要是大肠的功能。

Potassium salts are well absorbed from gastro intestinal tract. Net phosphorus absorption may occur in the small intestine in some species but is primarily a function of the colon in horses.

来源:DrugBank

吸收、分配和排泄

• 消除途径

钾主要通过肾脏排出。

Potassium is excreted primarily by kidney.

来源:DrugBank

吸收、分配和排泄

• 分布容积

分布主要是细胞内的，但主要是血管内的浓度负责毒性。

Distribution is largely intracellular, but it is the intravascular concentration that is primarily responsible for toxicity.

来源:DrugBank

吸收、分配和排泄

• 清除

磷酸盐通过透析被迅速清除。

Phosphates are rapidly cleared by dialysis.

来源:DrugBank

吸收、分配和排泄

钾盐从胃肠道被很好地吸收。钾主要通过肾脏排出。/POTASSIUM SALTS/

POTASSIUM SALTS ARE WELL ABSORBED FROM THE GASTROINTESTINAL TRACT. ... POTASSIUM IS EXCRETED PRIMARILY BY THE KIDNEY. /POTASSIUM SALTS/

来源:Hazardous Substances Data Bank (HSDB)

反应信息

• 作为反应物：
  描述：

  Phosphoric Acid Dipotassium 生成 Kaliumpyrophosphat
  参考文献：
  名称：

  SILANTEVA, N. I.;BOGDANOVA, G. A.;SOKOLOVA, M. E.;KAMENSKAYA, N. M.;FOMIN+

  摘要：

  DOI：
• 作为产物：
  描述：

  氢氧化钾 生成 Phosphoric Acid Dipotassium
  参考文献：
  名称：

  DULIMOVA, L. P.;ABDULINA, N. A.;GAFAROVA, A. F.;ZAJTSEV, V. A.;SAVINA, O.+, KAZ. NAUCH. ISSLED. I PROEKTN. IN-T FOS. PROM-TI, CHIMKENT,(1988) 7 S., O+

  摘要：

  DOI：
• 作为试剂：
  描述：

  3-acetoxymethyl-7(N-phenylacetyl-amino)-ceph-2-em-4xi-carboxylic acid 、 苯酚 在 Phosphoric Acid Dipotassium 、 乙酸乙酯 、 苯酚 、 氯化钠 、 Sodium sulfate-III 作用下， 以 三氟乙酸 、 甲苯 为溶剂， 反应 0.25h， 以yields 3-(4-hydroxy-benzyl)-7-(N-phenylacetyl-amino)-ceph-2-em-4ξ-carboxylic acid, which的产率得到3-(4-hydroxy-benzyl)-7-(N-phenylacetyl-amino)-ceph-2-em-4xi-carboxylic acid
  参考文献：
  名称：

  3-R-methyl-7-amino-ceph-em-4-carboxylic acid compounds

  摘要：

  3-R-甲基-7-氨基-头孢-2-乙烯-4.xi.-羧酸化合物，其中R是C-亲核化合物的C-残基，是有价值的中间体，例如，在制造具有抗生素性质的相应的3-R-甲基-7-氨基-头孢-3-乙烯-4-羧酸化合物方面。

  公开号：

  US03932465A1

文献信息

• IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20150094297A1

  公开（公告）日：2015-04-02

  The present invention provides thiazole compounds of Formula I wherein W, Y, R 0 , R 2 , R 4 , R 5 , R 6 , R 7 , X 1 , X 2 , X 3 and X 4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.

  本发明提供了式I的噻唑化合物，其中W、Y、R0、R2、R4、R5、R6、R7、X1、X2、X3和X4如本文所定义，或其立体异构体、互变异构体、药学上可接受的盐、前药酯或其溶剂化合物形式，其中所有变量均如本文所定义。这些化合物是血小板聚集抑制剂，因此可用作治疗或预防血栓栓塞性疾病的药物。
• Novel inhibitors of kinases
  申请人：——

  公开号：US20040072832A1

  公开（公告）日：2004-04-15

  The present invention provides compounds of formula I, 1 and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.

  本发明提供了I式化合物及其药学上可接受的盐。式I化合物能够抑制生长因子受体如VEGFR-2和FGFR-1的酪氨酸激酶活性，因此可用作抗癌剂。式I化合物还可用于治疗与通过生长因子受体进行信号转导途径相关的其他疾病。
• Microbiological process for the production of 7-substituted 11-hydroxy steroids, 7,17-substituted 11-halogen steroids that can be produced therefrom, their process for production and use as well as pharmaceutical prepartions that contain these compounds, as well as 7-substituted estra-1,3,5(10)-trienses that can be produced therefrom
  申请人：Zorn Ludwig

  公开号：US20050090477A1

  公开（公告）日：2005-04-28

  A novel method of synthesis for the manufacture of upstream products for the production of compounds with general formulas 8, 10, and 12 is described. In this synthesis, compounds with general formula 4,B are produced in a microbiological reaction. The meanings of R 7 , R 10 , R 11 , R 13 , R 17 and R 17′ as well as of the grouping U-V-W-X-Y-Z are indicated in the claims.

  本文介绍了一种新的合成方法，用于制造通式为8、10和12的化合物的上游产品。在这种合成中，通式为4-B的化合物是通过微生物反应产生的。在权利要求中指出了R7、R10、R11、R13、R17和R17'的含义，以及U-V-W-X-Y-Z的分组。
• Substituted imidazo-fused 5-membered ring heterocycles as angiotensin II
  申请人：Merck & Co., Inc.

  公开号：US05389660A1

  公开（公告）日：1995-02-14

  There are disclosed new substituted imidazo-fused 5-membered ring heterocyclic compounds and derivatives thereof which are useful as angiotensin II antagonists. These compounds have the general formula: ##STR1##

  本发明涉及新的取代的咪唑融合5元环杂环化合物及其衍生物，它们可用作血管紧张素II拮抗剂。这些化合物的一般式为：##STR1##
• 9-Substituted-4-oxopyrido(1,2-.alpha.)pyrimidine-3-carboxylic acids and
  申请人：E. R. Squibb & Sons, Inc.

  公开号：US03960847A1

  公开（公告）日：1976-06-01

  9-Substituted-4-oxopyrido[1,2-.alpha.]pyrimidine-3-carboxylic acids and related compounds are disclosed. In addition, their methods of preparation and use as central nervous system depressants and hypotensive agents are taught.

  本发明公开了9-取代-4-氧代吡啶[1,2-α]嘧啶-3-羧酸及其相关化合物。此外，本发明还教授了它们的制备方法以及作为中枢神经系统抑制剂和降压剂的用途。

表征谱图